{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054726","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.905604+00:00","generated_at":"2026-06-02T18:04:05.505707+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program","bullets":["Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.","Expected severance and related costs $3.1–3.2M, including ~$1.6M non-cash equity vesting; costs payable through Q4 2024.","Board member Rachelle Jacques resigned May 7, 2024; board reduced to five members with no disagreement reported.","Reduction is part of restructuring to cut HSCT-TMA operating costs and support long-term strategic plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054726","json":"https://secwatch.observer/filing/0000950170-24-054726.json","markdown":"https://secwatch.observer/filing/0000950170-24-054726.md","text":"https://secwatch.observer/filing/0000950170-24-054726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/aktx-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:04:05.505707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b3b78a52b","claim":"Rachelle Jacques resigned as Director at Akari Therapeutics Plc.","evidence_excerpt":"On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3addb9b1bb4bf92e8969223d43bf5627a7c951ac","claim":"Akari Therapeutics Plc announced a restructuring with charges of approximately $3.1 million to $3.2 million (approximately 67% of its total workforce).","evidence_excerpt":"expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.1 million to $3.2 million"},{"label":"Headcount","value":"approximately 67% of its total workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}